Nkarta shares NKX019 B-cell reconstitution and PK data from Phase 1 NHL trial

Nkarta, Inc.

After NKX019 treatment, circulating CD19+ cells rapidly depleted; B-cell repertoire recovered with naïve, non-class-switched isotypes in 5 patients at 3 months.
No patients had prior CAR T therapy; recovery pattern consistent with CAR T experience in autoimmune disease.
Preliminary PK data from 2 patients with DLBCL show similar NKX019 exposure after Flu/Cy vs Cy alone lymphodepletion.
B-cell recovery confirmed by single-cell RNA profiling, showing naïve and intermediate B cell transcriptome profiles.
Company highlights potential of NKX019 for autoimmune diseases such as lupus nephritis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.